Page results
-
The support and information specialists were shortlisted for a self-care innovation award. The award recognises the achievements of the team in developing and delivering a package of support for…
-
The oesophagus is the muscular tube which allows food to pass down from your mouth into your stomach. When the stomach contents wash back up from your stomach into your oesophagus, this is called…
-
The oesophagus is the muscular tube which allows food to pass down from your mouth into your stomach. When the stomach contents wash back up from your stomach into your oesophagus, this is called…
-
This page explains the options for sensitive handling of pregnancy tissue.
-
November is men’s health month (Movember), we are hosting our first public Live Q&A event via MS Teams.
-
If ataxia runs in your family, you can get tested to see if you have the genetic mistake for it Ataxia is a health condition that causes problems with movement…
-
Joint dislocations and subluxations can commonly occur in patients diagnosed with hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorders (HSD). Such events can be very…
-
COVID-19 information for patients and visitors Patients Please continue to attend hospital if you have an appointment or a medical emergency. If you need emergency treatment for symptoms…
File results
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer